Press Release

Partnership between RAMCON and Cytosurge

 Share 



RAMCON now offers unique single cell manipulation solutions from Cytosurge in the Nordics


Zurich | January 27, 2021

We are delighted to announce that RAMCON has been appointed as distributor in the Nordic Countries. RAMCON will distribute our FluidFM BIO Series lab solutions that enable cutting-edge experiments in life sciences and nanotechnology – from neuronal cell network patterning and multiplexed CRISPR gene editing to unprecedented fast cell line development – in Denmark, Finland, Norway, and Sweden. We are excited about the partnership and look forward to a fruitful collaboration.



 

Contact

Cytosurge AG
Claudia Frey
claudia.frey@cytosurge.com, +41 43 544 87 20




About RAMCON

RAMCON was established in 1988, and is today a modern company with more than 60 employees in sales, support and service. RAMCON focuses on these three core areas, and targets the Industrial, Medical, Chemical and Life Science market in the Nordic countries. RAMCON currently have 4 offices placed in Birkeröd, Vejle, Gothenburg and Stockholm.

RAMCON is a focused distributor with a robust organization with a high level of professionalism. The company is ISO 9001:2015 certified and consist of competent and well educated employees. Our strength is to know our customers' needs as well as a vast knowledge of the Industrial, Medical, Chemical and Life Science market. RAMCON constantly strives to be an organization characterized by a positive social atmosphere. We value integrity and respect for colleagues, customers and partners very highly. We invest in people as the primary marketing resource and offer a high level of service and support to our customers. It is the company's strategy to build good and lasting customer relations.

For more information, visit www.ramcon.eu. 


About Cytosurge

Cytosurge AG develops, manufactures and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the hollow FluidFM probes, which have apertures down to 300 nm, enabling the handling of femtoliter volumes.

Cytosurge brings with its FluidFM solutions significant benefits to a wide range of applications in life sciences, biophysics and mechanobiology. Unique benefits include quantitative volume measurements of injected compounds into single cells during drug development, improved CRISPR gene editing by direct delivery into the nucleus, isolation of selected cells directly from confluent culture, 2.5D nano-printing down to submicron levels, or single cell adhesion and colloidal probe measurements.

For more information, visit www.cytosurge.com. 



THIS NEWS HAS ALSO BEEN PUBLISHED BY:

RAMCON